

## Colchicine for COVID-19

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

# **Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial**

**Running title:** Colchicine for COVID-19

**RECOVERY Collaborative Group\***

\*The writing committee and trial steering committee are listed at the end of this manuscript and a complete list of collaborators in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix.

Correspondence to: Prof Peter W Horby and Prof Martin J Landray, RECOVERY Central Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom.

Email: [recoverytrial@ndph.ox.ac.uk](mailto:recoverytrial@ndph.ox.ac.uk)

Word count:

Abstract – 267 words

Main text – 2950 words

References – 27

Tables & Figures – 2 + 3

## Colchicine for COVID-19

### 28 **SUMMARY**

29 **Background:** Colchicine has been proposed as a treatment for COVID-19 on the basis  
30 of its anti-inflammatory actions.

31 **Methods:** In this randomised, controlled, open-label trial, several possible treatments  
32 were compared with usual care in patients hospitalised with COVID-19. Eligible and  
33 consenting adults were randomly allocated in a 1:1 ratio to either usual standard of care  
34 alone or usual standard of care plus colchicine twice daily for 10 days or until discharge  
35 (or one of the other treatment arms) using web-based simple (unstratified) randomisation  
36 with allocation concealment. The primary outcome was 28-day mortality. The trial is  
37 registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

38 **Findings:** Between 27 November 2020 and 4 March 2021, 5610 patients were randomly  
39 allocated to receive colchicine and 5730 patients to receive usual care alone. Overall,  
40 1173 (21%) patients allocated to colchicine and 1190 (21%) patients allocated to usual  
41 care died within 28 days (rate ratio 1.01; 95% confidence interval [CI] 0.93-1.10;  $p=0.77$ ).  
42 Consistent results were seen in all pre-specified subgroups of patients. There was no  
43 significant difference in duration of hospitalisation (median 10 days vs. 10 days) or the  
44 proportion of patients discharged from hospital alive within 28 days (70% vs. 70%; rate  
45 ratio 0.98; 95% CI 0.94-1.03;  $p=0.44$ ). Among those not on invasive mechanical  
46 ventilation at baseline, there was no significant difference in the proportion meeting the  
47 composite endpoint of invasive mechanical ventilation or death (25% vs. 25%; risk ratio  
48 1.02; 95% CI 0.96-1.09;  $p=0.47$ ).

## Colchicine for COVID-19

49 **Interpretation:** In adults hospitalised with COVID-19, colchicine was not associated with  
50 reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive  
51 mechanical ventilation or death.

52 **Funding:** UK Research and Innovation (Medical Research Council) and National Institute  
53 of Health Research (Grant ref: MC\_PC\_19056). Wellcome Trust (Grant Ref:  
54 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator.

55 **Keywords:** COVID-19, colchicine, clinical trial.

56

## Colchicine for COVID-19

### 57 **INTRODUCTION**

58 Inflammation is a key feature of severe COVID-19. Markedly raised levels of inflammatory  
59 markers such as C-reactive protein (CRP), ferritin, interleukin-6 (IL-6) and other cytokines  
60 are observed in severe cases and are associated with poor outcomes.<sup>1-5</sup> Inflammation is  
61 particularly prominent in the lung and vascular endothelium, and is commonly associated  
62 with extensive alveolar damage and thrombosis of large and small pulmonary vessels.<sup>6</sup>  
63 Corticosteroids and interleukin-6 inhibitors have both been shown to reduce mortality in  
64 patients with severe COVID-19, while Janus kinase (JAK) inhibitors accelerate  
65 improvement in clinical status.<sup>7-10</sup> Together these results show that inflammation is  
66 modifiable and anti-inflammatory therapy can improve clinical outcomes.

67 Inflammasomes are a key part of the innate immune response to SARS-CoV-2 infection.  
68 These cytosolic pattern recognition receptor systems are activated in response to  
69 detection of pathogens in the cytosol and stimulate the release of proinflammatory  
70 cytokines.<sup>11</sup> In COVID-19, the degree of inflammasome activation, particularly the  
71 nucleotide binding domain (NOD)-like pyrin domain 3 (NLRP3) inflammasome, correlates  
72 with disease severity.<sup>12</sup> Colchicine, a readily available, safe and inexpensive drug, has a  
73 wide range of anti-inflammatory effects, including inhibition of the NLRP3  
74 inflammasome.<sup>13</sup> In addition to its role in treating acute gout and pericarditis, there is  
75 emerging evidence that colchicine may inhibit endovascular inflammation and provide  
76 clinical benefits in patients with coronary artery disease.<sup>14-17</sup> Given the activation of  
77 NLRP3 in COVID-19 and the presence of vascular endothelial inflammation, colchicine  
78 has been proposed as a treatment for SARS-CoV-2 associated inflammatory disease.

## Colchicine for COVID-19

79 However, only three small randomised controlled trials have assessed the effects of  
80 colchicine in hospitalised patients and, with a total of only seven deaths across these  
81 studies combined, none were adequately powered to identify any impact on mortality.<sup>18-</sup>  
82 <sup>20</sup> Here we report the results of a large randomised controlled trial of colchicine in patients  
83 hospitalised with COVID-19.

84

### 85 **METHODS**

#### 86 **Study design and participants**

87 The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigator-  
88 initiated, individually randomised, controlled, open-label, platform trial to evaluate the  
89 effects of potential treatments in patients hospitalised with COVID-19. Details of the trial  
90 design and results for other possible treatments (dexamethasone, hydroxychloroquine,  
91 lopinavir-ritonavir, azithromycin, tocilizumab, and convalescent plasma) have been  
92 published previously.<sup>7,9,21-24</sup> The trial is underway at 177 hospitals in the United Kingdom  
93 supported by the National Institute for Health Research Clinical Research Network, two  
94 hospitals in Indonesia, and two hospitals in Nepal (appendix pp 3-25). The trial is  
95 coordinated by the Nuffield Department of Population Health at University of Oxford  
96 (Oxford, UK), the trial sponsor. The trial is conducted in accordance with the principles of  
97 the International Conference on Harmonisation–Good Clinical Practice guidelines and  
98 approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and  
99 the Cambridge East Research Ethics Committee (ref: 20/EE/0101). The protocol,

## Colchicine for COVID-19

100 statistical analysis plan, and additional information are available on the study website  
101 [www.recoverytrial.net](http://www.recoverytrial.net).

102 Patients admitted to hospital were eligible for the study if they had clinically suspected or  
103 laboratory confirmed SARS-CoV-2 infection and no medical history that might, in the  
104 opinion of the attending clinician, put the patient at significant risk if they were to  
105 participate in the trial. Children and pregnant women were not eligible for randomisation  
106 to colchicine. Patients with severe liver impairment, significant cytopaenia, concomitant  
107 use of strong CYP3A4 or P-glycoprotein inhibitors, or hypersensitivity to lactose were  
108 excluded (further details in appendix p 80). Written informed consent was obtained from  
109 all patients, or a legal representative if patients were too unwell or unable to provide  
110 consent.

### 111 **Randomisation and masking**

112 Baseline data were collected using a web-based case report form that included  
113 demographics, level of respiratory support, major comorbidities, suitability of the study  
114 treatment for a particular patient, and treatment availability at the study site (appendix pp  
115 32-34). Eligible and consenting, non-pregnant adult patients were assigned in a 1:1 ratio  
116 to either usual standard of care or usual standard of care plus colchicine or one of the  
117 other available RECOVERY treatment arms using web-based simple (unstratified)  
118 randomisation with allocation concealed until after randomisation (appendix pp 30-31).  
119 For some patients, colchicine was unavailable at the hospital at the time of enrolment or  
120 was considered by the managing physician to be either definitely indicated or definitely  
121 contraindicated. These patients were excluded from the randomised comparison between

## Colchicine for COVID-19

122 colchicine and usual care. Patients allocated to colchicine were to receive 1 mg after  
123 randomisation followed by 500 mcg 12 hours later and then 500 mcg twice daily by mouth  
124 or nasogastric tube for 10 days in total or until discharge, whichever occurred earlier.  
125 Dose frequency was halved for patients receiving a moderate CYP3A4 inhibitor or who  
126 had renal impairment (estimated glomerular filtration rate  $<30$  ml/min/1.73m<sup>2</sup>) or  
127 estimated body weight  $<70$  kg (appendix p 80).

128 As a platform trial, and in a factorial design, patients could be simultaneously randomised  
129 to other treatment groups: i) convalescent plasma versus monoclonal antibody (REGN-  
130 CoV2) versus usual care, ii) aspirin versus usual care, and iii) baricitinib versus usual care  
131 (appendix pp 31). Until 24 January 2021, the trial also allowed a subsequent  
132 randomisation for patients with progressive COVID-19 (evidence of hypoxia and a hyper-  
133 inflammatory state) to tocilizumab versus usual care. Participants and local study staff  
134 were not masked to the allocated treatment. The trial steering committee, investigators,  
135 and all other individuals involved in the trial were masked to outcome data during the trial.

136

### 137 **Procedures**

138 A single online follow-up form was completed when participants were discharged, had  
139 died or at 28 days after randomisation, whichever occurred earliest (appendix pp 35-41).  
140 Information was recorded on adherence to allocated study treatment, receipt of other  
141 COVID-19 treatments, duration of admission, receipt of respiratory or renal support, and  
142 vital status (including cause of death). In addition, in the UK, routine healthcare and  
143 registry data were obtained including information on vital status (with date and cause of

## Colchicine for COVID-19

144 death), discharge from hospital, receipt of respiratory support, or renal replacement  
145 therapy.

### 146 **Outcomes**

147 Outcomes were assessed at 28 days after randomisation, with further analyses specified  
148 at 6 months. The primary outcome was all-cause mortality. Secondary outcomes were  
149 time to discharge from hospital, and, among patients not on invasive mechanical  
150 ventilation at randomisation, invasive mechanical ventilation (including extra-corporal  
151 membrane oxygenation) or death. Prespecified subsidiary clinical outcomes were use of  
152 non-invasive respiratory support, time to successful cessation of invasive mechanical  
153 ventilation (defined as cessation of invasive mechanical ventilation within, and survival to,  
154 28 days), use of renal dialysis or haemofiltration, cause-specific mortality, bleeding  
155 events, thrombotic events, and major cardiac arrhythmias. Information on suspected  
156 serious adverse reactions was collected in an expedited fashion to comply with regulatory  
157 requirements.

### 158 **Statistical Analysis**

159 The primary analysis for all outcomes was by intention-to-treat comparing patients  
160 randomised to colchicine with patients randomised to usual care but for whom colchicine  
161 was both available and suitable as a treatment. For the primary outcome of 28-day  
162 mortality, the log-rank observed minus expected statistic and its variance were used to  
163 both test the null hypothesis of equal survival curves (i.e., the log-rank test) and to  
164 calculate the one-step estimate of the average mortality rate ratio. We constructed  
165 Kaplan-Meier survival curves to display cumulative mortality over the 28-day period. We

## Colchicine for COVID-19

166 used the same method to analyse time to hospital discharge and successful cessation of  
167 invasive mechanical ventilation, with patients who died in hospital right-censored on day  
168 29. Median time to discharge was derived from Kaplan-Meier estimates. For the pre-  
169 specified composite secondary outcome of progression to invasive mechanical ventilation  
170 or death within 28 days (among those not receiving invasive mechanical ventilation at  
171 randomisation), and the subsidiary clinical outcomes of receipt of ventilation and use of  
172 haemodialysis or haemofiltration, the precise dates were not available and so the risk  
173 ratio was estimated instead.

174 Prespecified analyses were performed for the primary outcome using the statistical test  
175 of interaction (test for heterogeneity or trend), in accordance with the prespecified  
176 analysis plan, defined by characteristics at randomisation: age, sex, ethnicity, level of  
177 respiratory support, days since symptom onset, and use of corticosteroids (appendix p  
178 114).

179 Estimates of rate and risk ratios are shown with 95% confidence intervals. All p-values  
180 are 2-sided and are shown without adjustment for multiple testing. The full database is  
181 held by the study team which collected the data from study sites and performed the  
182 analyses at the Nuffield Department of Population Health, University of Oxford (Oxford,  
183 UK).

184 As stated in the protocol, appropriate sample sizes could not be estimated when the trial  
185 was being planned at the start of the COVID-19 pandemic (appendix p 54). As the trial  
186 progressed, the trial steering committee, whose members were unaware of the results of  
187 the trial comparisons, determined that sufficient patients should be enrolled to provide at

## Colchicine for COVID-19

188 least 90% power at a two-sided significance level of 0.01 to detect a clinically relevant  
189 proportional reduction in 28-day mortality of 12.5% between the two groups.

190 On 4 March 2021, the independent data monitoring committee (DMC) conducted a routine  
191 review of the available safety and efficacy data. The DMC notified the chief investigators  
192 that there was no convincing evidence that further recruitment to the colchicine  
193 comparison would provide conclusive proof of worthwhile mortality benefit either overall  
194 or in any pre-specified subgroup. Consequently, recruitment to the colchicine comparison  
195 was closed on 5 March 2021 and preliminary results were made available to the public.

196 Analyses were performed using SAS version 9.4 and R version 3.4. The trial is registered  
197 with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

### 198 **Role of the funding source**

199 The funder of the study had no role in study design, data collection, data analysis, data  
200 interpretation, or writing of the report. The corresponding authors had full access to all the  
201 data in the study and had final responsibility for the decision to submit for publication.

202

### 203 **RESULTS**

204 Between 27 November 2020 and 4 March 2021, 11,340 (58%) of 19423 patients enrolled  
205 into the RECOVERY trial were eligible to be randomly allocated to colchicine (i.e.  
206 colchicine was available in the hospital at the time and the attending clinician was of the  
207 opinion that the patient had no known indication for or contraindication to colchicine, figure

## Colchicine for COVID-19

208 1). 5610 patients were randomly allocated to colchicine and 5730 were randomly  
209 allocated to usual care (36 patients were randomised outside of UK). The mean age of  
210 study participants in this comparison was 63.4 years (SD 13.8) and the median time since  
211 symptom onset was 9 days (IQR 6 to 12 days) (webtable 1). At randomisation, 10603  
212 (94%) of patients were receiving corticosteroids.

213 The follow-up form was completed for 5510 (98%) in the colchicine group and 5605 (98%)  
214 in the usual care group. Among patients with a completed follow-up form, 5122 (93%)  
215 allocated to colchicine received at least one dose (figure 1; webtable 2). The median  
216 duration of treatment with colchicine was 6 days (IQR 3-9 days). Use of other treatments  
217 for COVID-19 was similar among patients allocated colchicine and among those allocated  
218 usual care, with 87% receiving a corticosteroid, about one-quarter receiving remdesivir,  
219 and one-eighth receiving tocilizumab (webtable 2).

220 Primary and secondary outcome data are known for >99% of randomly assigned patients.  
221 There was no significant difference in the proportion of patients who met the primary  
222 outcome of 28-day mortality between the two randomised groups (1173 [21%] patients in  
223 the colchicine group vs. 1190 (21%) patients in the usual care group; rate ratio 1.01; 95%  
224 confidence interval [CI], 0.93 to 1.10;  $p=0.77$ ; figure 2). We observed similar results  
225 across all pre-specified sub-groups (figure 3). In an exploratory analysis restricted to the  
226 11009 (97%) patients with a positive SARS-CoV-2 test result, the result was virtually  
227 identical (rate ratio 1.02, 95% CI 0.94 to 1.10;  $p=0.70$ ).

228 The median time to discharge from hospital alive was 10 days (IQR 5 to >28) in both  
229 groups and there was no significant difference in the probability of being discharged alive

## Colchicine for COVID-19

230 within 28 days (70% vs. 70%, rate ratio 0.98, 95% CI 0.94 to 1.03,  $p=0.44$ ) (table 2).

231 Among those not on invasive mechanical ventilation at baseline, the number of patients  
232 progressing to the pre-specified composite secondary outcome of invasive mechanical  
233 ventilation or death was similar in both groups (25% vs. 25%, risk ratio 1.02, 95% CI 0.96  
234 to 1.09,  $p=0.47$ ). Similar results were seen in all pre-specified subgroups of patients  
235 (webfigure 1, webfigure 2).

236 We found no significant differences in the prespecified subsidiary clinical outcomes of  
237 cause-specific mortality (webtable 3), use of ventilation, successful cessation of invasive  
238 mechanical ventilation, or need for renal dialysis or haemofiltration (table 2). The  
239 incidence of new cardiac arrhythmias, bleeding events, and thrombotic events was also  
240 similar in the two groups (webtable 4). There were two reports of a serious adverse  
241 reaction believed related to colchicine: one case of severe acute kidney injury and one  
242 case of rhabdomyolysis.

243

## 244 **DISCUSSION**

245 In this large, randomised trial involving over 11,000 patients from 3 countries and over  
246 2000 deaths, allocation to colchicine was not associated with reductions in mortality,  
247 duration of hospitalisation or the risk of being ventilated or dying for those not on  
248 ventilation at baseline. These results were consistent across the prespecified subgroups  
249 of age, sex, ethnicity, duration of symptoms prior to randomisation, level of respiratory  
250 support at randomisation, and use of corticosteroids.

## Colchicine for COVID-19

251 The benefit of dexamethasone in COVID-19 patients requiring respiratory support  
252 demonstrates the importance of inflammation in this patient group and colchicine was  
253 proposed as a treatment for COVID-19 based on its anti-inflammatory activity.<sup>25</sup> The lack  
254 of evidence of benefit from colchicine in this large well-powered trial suggests that the  
255 anti-inflammatory properties of colchicine are either insufficient to produce a meaningful  
256 reduction in mortality risk or are not affecting the relevant inflammatory pathways in  
257 moderate to severe COVID-19. Whilst the majority of patients in this study received  
258 concomitant corticosteroid therapy, we saw no evidence that colchicine was beneficial in  
259 those patients not receiving a corticosteroid.

260 Strengths of this trial included that it was randomised, had a large sample size, broad  
261 eligibility criteria, was international and more than 99% of patients were followed up for  
262 the primary outcome. However, detailed information on laboratory markers of  
263 inflammation and immune response was not collected, nor was information on  
264 radiological or physiological outcomes. Although this randomised trial is open label (i.e.,  
265 participants and local hospital staff are aware of the assigned treatment), the outcomes  
266 are unambiguous and were ascertained without bias through linkage to routine health  
267 records.

268 Three other randomised controlled trials have assessed the efficacy of colchicine for the  
269 treatment of COVID-19 in hospitalised patients.<sup>18-20</sup> A two day shorter duration of  
270 hospitalisation was reported in a trial of 100 patients with laboratory confirmed SARS-  
271 CoV-2 infection and pulmonary involvement on computed tomography who were  
272 randomized to either hydroxychloroquine plus colchicine or hydroxychloroquine plus

## Colchicine for COVID-19

273 placebo.<sup>18</sup> A second trial reported a reduced duration of hospitalisation and oxygen  
274 therapy in 36 in-patients allocated colchicine compared to 36 in-patients allocated usual  
275 care, which included hydroxychloroquine, azithromycin and methylprednisolone.<sup>19</sup>  
276 Finally, the GRECCO-19 trial reported a lower rate of clinical deterioration in 55 patients  
277 randomly assigned to colchicine compared to 50 patients randomly assigned to usual  
278 care (which did not include corticosteroids).<sup>20</sup> The total number of patients in all three  
279 prior trials combined was 285 with seven deaths during the follow-up period. By contrast,  
280 the RECOVERY trial, with more than 11,000 participants and more than 2,000 deaths,  
281 had excellent power to detect modest treatment benefits; none were observed.

282 The RECOVERY trial only studied patients who had been hospitalised with COVID-19  
283 and, therefore, is not able to provide any evidence on the safety and efficacy of colchicine  
284 used in other patient groups. In the COLCORONA trial of 4488 non-hospitalised patients  
285 with laboratory confirmed or clinically suspected COVID-19, fewer patients in the  
286 colchicine group met the composite endpoint of death or hospitalisation within 30 days of  
287 randomization than in the placebo group. However, the trial was stopped before the  
288 scheduled sample size had been fully enrolled due to logistical reasons and the result  
289 was not statistically significant (odds ratio, 0.79; 95% CI 0.61 to 1.03; P=0.08).<sup>26</sup> Thus the  
290 role of colchicine in treatment of COVID-19 among patients not requiring hospitalisation  
291 remains uncertain. Further trials in that setting are ongoing.<sup>27</sup>

292 In summary, the results of this large, randomised trial do not support the use of colchicine  
293 in adults hospitalised with COVID-19.

294

## Colchicine for COVID-19

### 295 **Evidence before this study:**

296 We searched medRxiv, bioRxiv, Medline, Embase and the WHO International Clinical  
297 Trials Registry Platform from September 1, 2019 to April 1, 2021 for clinical trials  
298 evaluating the effect of colchicine treatment among patients hospitalised with COVID-19,  
299 using the search terms (“SARS-CoV-2.mp” OR “COVID.mp” OR “COVID-19.mp” OR  
300 “2019-nCoV.mp” OR “Coronavirus.mp” OR “Coronavirinae/”) AND (“colchicine.mp” OR  
301 “colchicine/”) in any language, using validated filters to select for randomised controlled  
302 trials.

303

304 We identified three relevant randomised trials that compared colchicine with usual care  
305 or placebo in hospitalised patients with COVID-19 (two at low risk of bias and one with  
306 some concerns due to limited information on randomisation process and lack of clarity  
307 about blinding in the study). Each trial suggested a potential favourable impact of  
308 colchicine on outcome measures of clinical improvement or duration of hospitalisation,  
309 The three trials combined included a total of 285 patients and 7 deaths, so even combined  
310 were not adequately powered to detect an effect on mortality.

311

### 312 **Added value of this study:**

313 The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is the first large,  
314 randomised trial to report results of the effect of colchicine in patients hospitalised with  
315 COVID-19. We found no significant effect of colchicine vs. usual care alone on 28-day  
316 mortality, the probability of discharge alive within 28 days, or, among patients who were  
317 not receiving invasive mechanical ventilation at randomisation, the probability of

## Colchicine for COVID-19

318 progressing to the composite outcome of invasive mechanical ventilation or death. We  
319 saw no evidence of benefit of colchicine in any patient subgroup.

320

321 **Implications of all the available evidence:**

322 Colchicine treatment is not of clinical benefit for adults hospitalised with COVID-19  
323 compared with current usual care.

324

## Colchicine for COVID-19

### 325 **Contributors**

326 This manuscript was initially drafted by the PWH and MJL, further developed by the  
327 Writing Committee, and approved by all members of the trial steering committee. PWH  
328 and MJL vouch for the data and analyses, and for the fidelity of this report to the study  
329 protocol and data analysis plan. PWH, JKB, MB, LCC, JD, SNF, TJ, EJ, KJ, WSL, AMo,  
330 AMu, KR, GT, MM, RH, and MJL designed the trial and study protocol. MM, MC, G P-A,  
331 LP, MW, LW, ST, BC, CW, CG, PH, BP, TG, AW, the Data Linkage team at the  
332 RECOVERY Coordinating Centre, and the Health Records and Local Clinical Centre staff  
333 listed in the appendix collected the data. ES, NS, and JRE did the statistical analysis. All  
334 authors contributed to data interpretation and critical review and revision of the  
335 manuscript. PWH and MJL had access to the study data and had final responsibility for  
336 the decision to submit for publication.

337

## Colchicine for COVID-19

### 338 **Writing Committee (on behalf of the RECOVERY Collaborative Group):**

339 Peter W Horby PhD FRCP, Mark Campbell FRCPATH, Enti Spata, Jonathan R Emberson  
340 PhD, Natalie Staplin PhD, Guilherme Pessoa-Amorim, Leon Peto PhD, Martin Wiselka  
341 PhD, Laura Wiffen MRCP, Simon Tiberi FRCP, Ben Caplin PhD, Caroline Wroe PhD,  
342 Christopher Green DPhil, Paul Hine MRCP, Benjamin Prudon FRCP (Edin), Tina George  
343 MRCP, Andrew Wight MRCP, J Kenneth Baillie MD PhD, Buddha Basnyat, Maya Buch  
344 PhD FRCP, Lucy C Chappell PhD, Jeremy Day PhD FRCP, Saul N Faust FRCPCH, Raph  
345 L Hamers, Thomas Jaki PhD, Edmund Juszczak MSc, Katie Jeffery PhD, Wei Shen Lim  
346 FRCP, Alan Montgomery PhD, Andrew Mumford PhD, Kathryn Rowan PhD, Guy  
347 Thwaites PhD FRCP, Marion Mafham MD, Richard Haynes DM, Martin J Landray PhD  
348 FRCP.

### 349 **Data Monitoring Committee**

350 Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Lalloo,  
351 Mohammed Munavvar (from January 2021), Ian Roberts (until December 2020), Janet  
352 Wittes.

### 353 **Declaration of interests**

354 The authors have no conflict of interest or financial relationships relevant to the submitted  
355 work to disclose. No form of payment was given to anyone to produce the manuscript. All  
356 authors have completed and submitted the ICMJE Form for Disclosure of Potential  
357 Conflicts of Interest. The Nuffield Department of Population Health at the University of  
358 Oxford has a staff policy of not accepting honoraria or consultancy fees directly or

## Colchicine for COVID-19

359 indirectly from industry (see <https://www.ndph.ox.ac.uk/files/about/ndph-independence->  
360 [of-research-policy-jun-20.pdf](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)).

### 361 **Data sharing**

362 The protocol, consent form, statistical analysis plan, definition & derivation of clinical  
363 characteristics & outcomes, training materials, regulatory documents, and other relevant  
364 study materials are available online at [www.recoverytrial.net](http://www.recoverytrial.net). As described in the protocol,  
365 the trial Steering Committee will facilitate the use of the study data and approval will not  
366 be unreasonably withheld. Deidentified participant data will be made available to bona  
367 fide researchers registered with an appropriate institution within 3 months of publication.  
368 However, the Steering Committee will need to be satisfied that any proposed publication  
369 is of high quality, honours the commitments made to the study participants in the consent  
370 documentation and ethical approvals, and is compliant with relevant legal and regulatory  
371 requirements (e.g. relating to data protection and privacy). The Steering Committee will  
372 have the right to review and comment on any draft manuscripts prior to publication. Data  
373 will be made available in line with the policy and procedures described at:  
374 <https://www.ndph.ox.ac.uk/data-access>. Those wishing to request access should  
375 complete the form at  
376 [https://www.ndph.ox.ac.uk/files/about/data\\_access\\_enquiry\\_form\\_13\\_6\\_2019.docx](https://www.ndph.ox.ac.uk/files/about/data_access_enquiry_form_13_6_2019.docx)  
377 and e-mailed to: [data.access@ndph.ox.ac.uk](mailto:data.access@ndph.ox.ac.uk)

378

### 379 **Acknowledgements**

## Colchicine for COVID-19

380 Above all, we would like to thank the thousands of patients who participated in this trial.  
381 We would also like to thank the many doctors, nurses, pharmacists, other allied health  
382 professionals, and research administrators at 177 NHS hospital organisations across the  
383 whole of the UK, supported by staff at the National Institute of Health Research (NIHR)  
384 Clinical Research Network, NHS DigiTrials, Public Health England, Department of Health  
385 & Social Care, the Intensive Care National Audit & Research Centre, Public Health  
386 Scotland, National Records Service of Scotland, the Secure Anonymised Information  
387 Linkage (SAIL) at University of Swansea, and the NHS in England, Scotland, Wales and  
388 Northern Ireland.

389 The RECOVERY trial is supported by grants to the University of Oxford from UK Research  
390 and Innovation (UKRI) and NIHR (MC\_PC\_19056), the Wellcome Trust (Grant Ref:  
391 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator, and by core funding  
392 provided by the NIHR Oxford Biomedical Research Centre, the Wellcome Trust, the Bill  
393 and Melinda Gates Foundation, the Foreign, Commonwealth and Development Office,  
394 Health Data Research UK, the Medical Research Council Population Health Research  
395 Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR  
396 Clinical Trials Unit Support Funding. TJ is supported by a grant from UK Medical  
397 Research Council (MC\_UU\_0002/14) and an NIHR Senior Research Fellowship (NIHR-  
398 SRF-2015-08-001). WSL is supported by core funding provided by NIHR Nottingham  
399 Biomedical Research Centre. Combiphar supplied colchicine free of charge for use in this  
400 trial in Indonesia. Tocilizumab was provided free of charge for this trial by Roche Products  
401 Limited. REGN-COV2 was provided free of charge for this trial by Regeneron.  
402 Convalescent plasma was collected by NHS Blood and Transplant, the Scottish National

## Colchicine for COVID-19

403 Blood Transfusion Service, Welsh Blood Service, Northern Ireland Blood Transfusion  
404 Service and funded by the DHSC through core funding and funding under COVID-19 and  
405 EU SoHo Grant.

406 The views expressed in this publication are those of the authors and not necessarily those  
407 of the NHS, the NIHR, or the UK Department of Health and Social Care.

### 408 **Conflicts of interest**

409 The authors have no conflict of interest or financial relationships relevant to the submitted  
410 work to disclose. No form of payment was given to anyone to produce the manuscript. All  
411 authors have completed and submitted the ICMJE Form for Disclosure of Potential  
412 Conflicts of Interest. The Nuffield Department of Population Health at the University of  
413 Oxford has a staff policy of not accepting honoraria or consultancy fees directly or  
414 indirectly from industry (see [https://www.ndph.ox.ac.uk/files/about/ndph-independence-](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)  
415 [of-research-policy-jun-20.pdf](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)).

416

## Colchicine for COVID-19

### 417 References

- 418 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019  
419 novel coronavirus in Wuhan, China. *Lancet* 2020.
- 420 2. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to  
421 COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive*  
422 *Care Med* 2020.
- 423 3. Wang JH, Chen RD, Yang HK, et al. Inflammation-associated factors for  
424 predicting in-hospital mortality in patients with COVID-19. *J Med Virol* 2021.
- 425 4. Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, et al. Inflammatory  
426 profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe  
427 COVID-19. *Sci Immunol* 2021; **6**(57).
- 428 5. McElvaney OJ, McEvoy NL, McElvaney OF, et al. Characterization of the  
429 Inflammatory Response to Severe COVID-19 Illness. *Am J Respir Crit Care Med* 2020;  
430 **202**(6): 812-21.
- 431 6. Dorward DA, Russell CD, Um IH, et al. Tissue-Specific Immunopathology in Fatal  
432 COVID-19. *Am J Respir Crit Care Med* 2021; **203**(2): 192-201.
- 433 7. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in  
434 Hospitalized Patients with Covid-19. *N Engl J Med* 2021; **384**(8): 693-704.
- 435 8. W. H. O. Rapid Evidence Appraisal for COVID-19 Therapies Working Group,  
436 Sterne JAC, Murthy S, et al. Association Between Administration of Systemic  
437 Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-  
438 analysis. *JAMA* 2020; **324**(13): 1330-41.
- 439 9. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital  
440 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.  
441 *Lancet* 2021; **397**(10285): 1637-45.
- 442 10. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for  
443 Hospitalized Adults with Covid-19. *N Engl J Med* 2020.
- 444 11. Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and  
445 signalling. *Nat Rev Immunol* 2016; **16**(7): 407-20.
- 446 12. Rodrigues TS, de Sa KSG, Ishimoto AY, et al. Inflammasomes are activated in  
447 response to SARS-CoV-2 infection and are associated with COVID-19 severity in  
448 patients. *J Exp Med* 2021; **218**(3).
- 449 13. Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colchicine in the  
450 treatment of gout. *Clin Ther* 2014; **36**(10): 1465-79.

## Colchicine for COVID-19

- 451 14. Fiolet ATL, Opstal TSJ, Mosterd A, et al. Efficacy and safety of low-dose  
452 colchicine in patients with coronary disease: a systematic review and meta-analysis of  
453 randomized trials. *Eur Heart J* 2021.
- 454 15. Martinez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the  
455 emerging role of colchicine to inhibit atherosclerosis-associated inflammation.  
456 *Atherosclerosis* 2018; **269**: 262-71.
- 457 16. Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute  
458 pericarditis. *N Engl J Med* 2013; **369**(16): 1522-8.
- 459 17. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine  
460 after Myocardial Infarction. *N Engl J Med* 2019; **381**(26): 2497-505.
- 461 18. Salehzadeh F, Pourfarzi F, Ataei S. The Impact of Colchicine on The COVID-19  
462 Patients; A Clinical Trial Study. *Research Square* 2021.
- 463 19. Lopes MI, Bonjorno LP, Giannini MC, et al. Beneficial effects of colchicine for  
464 moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled  
465 clinical trial. *RMD Open* 2021; **7**(1).
- 466 20. Devereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of Colchicine vs  
467 Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in  
468 Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized  
469 Clinical Trial. *JAMA Netw Open* 2020; **3**(6): e2013136.
- 470 21. RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of  
471 Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* 2020;  
472 **383**(21): 2030-40.
- 473 22. RECOVERY Collaborative Group, Horby PW, Mafham M, et al. Lopinavir-  
474 ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised,  
475 controlled, open-label, platform trial. *Lancet* 2020; **396**(10259 ): 1345-52.
- 476 23. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital  
477 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.  
478 *Lancet* 2021; **397**(10274): 605-12.
- 479 24. RECOVERY Collaborative Group, Horby PW, Estcourt L, et al. Convalescent  
480 plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised,  
481 controlled, open-label, platform trial. *medRxiv* 2021: 2021.03.09.21252736.
- 482 25. Devereos SG, Siasos G, Giannopoulos G, et al. The Greek study in the effects of  
483 colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and  
484 study design. *Hellenic J Cardiol* 2020; **61**(1): 42-5.
- 485 26. Tardif J-C, Bouabdallaoui N, L'Allier PL, et al. Efficacy of Colchicine in Non-  
486 Hospitalized Patients with COVID-19. *medRxiv* 2021: 2021.01.26.21250494.

## Colchicine for COVID-19

487 27. University of Oxford. PRINCIPLE COVID-19 treatments trial widens to under 50s  
488 and adds colchicine. 2021. [https://www.principletrial.org/news/principle-covid-19-](https://www.principletrial.org/news/principle-covid-19-treatments-trial-widens-to-under-50s-adds-colchicine)  
489 [treatments-trial-widens-to-under-50s-adds-colchicine](https://www.principletrial.org/news/principle-covid-19-treatments-trial-widens-to-under-50s-adds-colchicine) (accessed 11 March 2021).  
490

491

## Colchicine for COVID-19

### 492 **Figures**

#### 493 **Figure 1: Trial profile**

494 ITT=intention to treat. \* Number recruited overall during period that adult participants  
495 could be recruited into colchicine comparison. Of the 11,340 randomised to colchicine  
496 vs usual care, 7091 were additionally randomised to convalescent plasma vs  
497 REGN-COV2 vs usual care (3505 [62%] of the colchicine group vs 3586 [63%] of the  
498 usual care group); 7545 were additionally randomised to aspirin vs usual care (3747  
499 [67%] of the colchicine group vs 3798 [66%] of the usual care group), and 1635 patients  
500 were additionally randomised to baricitinib vs usual care (802 [14%] of the colchicine  
501 group vs 833 [15%] of the usual care group). † Includes 251/5610 (4%) patients in the  
502 colchicine arm and 306/5730 (5%) patients in the usual care arm allocated to  
503 tocilizumab.

#### 504 **Figure 2: Effect of allocation to colchicine on 28-day mortality**

#### 505 **Figure 3: Effect of allocation to colchicine on 28-day mortality by baseline** 506 **characteristics**

507 Subgroup-specific rate ratio estimates are represented by squares (with areas of the  
508 squares proportional to the amount of statistical information) and the lines through them  
509 correspond to the 95% CIs. The ethnicity, days since onset and use of corticosteroids  
510 subgroups exclude those with missing data, but these patients are included in the overall  
511 summary diamond.

512

## Colchicine for COVID-19

513 **Table 1: Baseline characteristics**

	Treatment allocation	
	Colchicine (n=5610)	Usual care (n=5730)
Age, years	63.3 (13.8)	63.5 (13.7)
<70	3806 (68%)	3850 (67%)
≥70 to <80	1139 (20%)	1227 (21%)
≥80	665 (12%)	653 (11%)
Sex		
Male	3896 (69%)	4012 (70%)
Female	1713 (31%)	1718 (30%)
Ethnicity		
White	4344 (77%)	4383 (76%)
Black, Asian, and minority ethnic	758 (14%)	813 (14%)
Unknown	508 (9%)	534 (9%)
Number of days since symptom onset	9 (6-12)	9 (6-12)
Number of days since admission to hospital	2 (1-3)	2 (1-3)
Respiratory support received		
None / simple oxygen	3815 (68%)	3962 (69%)
Non invasive ventilation	1527 (27%)	1507 (26%)
Invasive mechanical ventilation	268 (5%)	261 (5%)
Previous diseases		
Diabetes	1426 (25%)	1470 (26%)
Heart disease	1189 (21%)	1231 (21%)
Chronic lung disease	1208 (22%)	1206 (21%)
Tuberculosis	16 (<1%)	13 (<1%)
HIV	11 (<1%)	20 (<1%)
Severe liver disease *	0 (0%)	0 (0%)
Severe kidney impairment †	170 (3%)	166 (3%)
Any of the above	2880 (51%)	2963 (52%)
Use of corticosteroids		
Yes	5243 (93%)	5360 (94%)
No	363 (6%)	365 (6%)
Missing	4 (<1%)	5 (<1%)
Severe acute respiratory syndrome coronavirus 2 test result		
Positive	5456 (97%)	5553 (97%)
Negative	57 (1%)	58 (1%)
Unknown	97 (2%)	119 (2%)

Data are mean (SD), n (%), or median (IQR). No children or pregnant women were randomised. \* Defined as requiring ongoing specialist care. † Defined as estimated glomerular filtration rate <30 mL/min per 1.73 m<sup>2</sup>.

## Colchicine for COVID-19

515 **Table 2: Effect of allocation to colchicine on key study outcomes**

	Treatment allocation		RR (95% CI)	p-value
	Colchicine (n=5610)	Usual care (n=5730)		
<b>Primary outcome:</b>				
28-day mortality	1173 (21%)	1190 (21%)	1.01 (0.93-1.10)	0.77
<b>Secondary outcomes:</b>				
Median time to being discharged alive, days	10 (5 to >28)	10 (5 to >28)		
Discharged from hospital within 28 days	3901 (70%)	4032 (70%)	0.98 (0.94-1.03)	0.44
Receipt of invasive mechanical ventilation or death*	1344/5342 (25%)	1343/5469 (25%)	1.02 (0.96-1.09)	0.47
Invasive mechanical ventilation	600/5342 (11%)	591/5469 (11%)	1.04 (0.93-1.16)	0.48
Death	1053/5342 (20%)	1070/5469 (20%)	1.01 (0.93-1.09)	0.85
<b>Subsidiary clinical outcomes</b>				
Receipt of ventilation †	852/3815 (22%)	941/3962 (24%)	0.94 (0.87-1.02)	0.14
Non-invasive ventilation	818/3815 (21%)	904/3962 (23%)	0.94 (0.86-1.02)	0.14
Invasive mechanical ventilation	259/3815 (7%)	228/3962 (6%)	1.18 (0.99-1.40)	0.06
Successful cessation of invasive mechanical ventilation ‡	88/268 (33%)	81/261 (31%)	1.01 (0.75-1.37)	0.93
Use of haemodialysis or haemofiltration §	212/5570 (4%)	203/5683 (4%)	1.07 (0.88-1.29)	0.51


Data are n (%) or n/N (%), unless otherwise indicated. RR=rate ratio for the outcomes of 28-day mortality, hospital discharge and successful cessation of invasive mechanical ventilation, and risk ratio for other outcomes. \* Analyses exclude those on invasive mechanical ventilation at randomisation. † Analyses exclude those on any form of ventilation at randomisation. ‡ Analyses restricted to those on invasive mechanical ventilation at randomisation. § Analyses exclude those on haemodialysis or haemofiltration at randomisation.

516

517


# Figure 1: Trial profile

medRxiv preprint doi: <https://doi.org/10.1101/2021.05.18.21257267>; this version posted May 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



## Figure 2: Effect of allocation to colchicine on 28-day mortality

medRxiv preprint doi: <https://doi.org/10.1101/2021.05.18.21257267>; this version posted May 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



Number at risk	0	7	14	21	28
Active	5610	5083	4733	4526	4405
Control	5730	5217	4877	4631	4509

**Figure 3: Effect of allocation to colchicine on 28-day mortality by baseline characteristics**

